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ABSTRACT
A STUDY ON THE LOWER RESPIRATORY TRACT  INFECTIONS  IN POST
RENAL TRANSPLANT PATIENTS ATTENDING THE NEPHROLOGY
DEPARTMENT IN A TERTIARY CARE HOSPITAL WITH SPECIAL
REFERENCE TO OPPORTUNISTIC INFECTIONS
INTRODUCTION:
Infection is of major concern in renal transplant recipients as this creates a
vicious cycle . Infection leads to rejection and rejection in turn leads to infection.
Pneumonia is the second leading cause of infection in renal transplant recipients , (2.9-
30%)7,8,9 after urinary tract infection (23.6%) 13. This study deals with the prevalence of
lower respiratory tract infection  in post renal transplant recipients in our hospital.
AIIMS @ OBJECTIVES:
To determine the prevalence of lower respiratory tract infections in post renal
transplant recipients and its association with risk factors,
To look for the type of organism causing pneumonia  and its relation with
duration of  transplant,
To determine the antibiotic susceptibility pattern of bacterial infections.
MATERIALS & METHODS
Type of study:
Both prospective and retrospective study
Place of Study & Period of Study:
Department of  Microbiology, Stanley Medical college,
Department of Nephrology, Stanley Medical college.
Study period:
September  2014 to August 2015.
Sample size and Inclusion criteria:
A total of 147 post renal transplant recipients who are followed as
inpatients and outpatients in the Department of Nephrology, Stanley Medical College
were taken for the  study. The details of lower respiratory tract infection that occurred
previously  is collected from the patient's record and the newer samples were also
collected and processed from the patients with symptoms and signs of respiratory tract
infection .
Ethical Consideration
Ethical and research clearance was obtained from the Ethical committee,
Stanley Medical College.
Statistical Analysis
The collected data was analyzed with SPSS 21.0 version.
CONCLUSION
The prevalence of lower respiratory tract infection in renal transplant recipients in
our hospital is about 27.2%.
There was a higher incidence of fungal pneumonia in poorly controlled diabetes
patients.
Patients who received intravenous pulse methyl prednisolone for rejection had
higher incidence of bacterial infection.
Induction therapy was not associated with increase in incidence of infection.
Since patient is on lifelong prophylaxis of cotrimoxazole, there is a higher increase
of resistance to it.
INTRODUCTION
Transplantation medicine is one of the most challenging and complex areas
of modern medicine. The use of solid organ transplantation has been established as
accepted therapy for end-stage disease of the kidneys, liver, heart and lungs for nearly
30 years. According to the data  provided by the Global Observatory on Donation and
Transplantation (GODT)  114,690 solid organs are transplanted in 2012.  Living
kidney transplants constitutes about 42.3% of the transplants.
Renal transplantation is the transfer of kidney into a person with end stage
renal disease which is defined by Glomerular filtration rate < 15ml/min/1.73sqmm.
End stage disease of the kidney is most commonly caused by malignant hypertension,
diabetes mellitus, infection, focal segmental glomerulosclerosis, polycystic kidney
disease, inborn errors of metabolism, systemic lupus erythematosus. Most of the renal
transplant recipients are on dialysis at the time of transplant.
Though renal transplantation is considered  the most novel approach in
treating a patient with end stage renal disease, rejection is a major concern. The
recipient's immune system attacks the donor organ as foreign substance since it cannot
discriminate between harmful substances like bacteria, viruses, fungi and the
transplanted organ. Here comes the role of immunosuppressive  agents to control the
body's immune response. For the long term survival of both  the graft and the
recipients of both the living and deceased donor transplant recipients, almost all
patients require life time immunosuppression  and hence are at increased risk of
infection any time during their life period.
Infection is of major concern in renal transplant recipients as this creates a
vicious cycle . Infection leads to rejection and rejection in turn leads to infection.
Since pneumonia is the second leading cause of infection in renal transplant recipients
, (2.9-30%)7,8,9 after urinary tract infection (23.6%) 13, knowledge about its
prevalence, the type of organism causing, its pattern of resistance, the duration of its
occurrence time since transplant, its association with various immunosuppressive
drugs need to be known. Though there are various studies describing about them, it
cannot be universally applied, since each hospital follows a different protocol to treat
the renal transplant recipients.
Hence this study deals with the prevalence of lower respiratory tract
infection  in post renal transplant recipients in our hospital. The transplant recipients
receive induction agents and increased dose of maintenance immunosuppressive
regimens during the initial period. Anti rejection therapy  for acute rejection is given
within three months of transplant as they occur most commonly during this period.
Hence the study population is divided into 4 groups based on the time since transplant
1) Immediate post operative period,
2) Within 2 months,
3) >2 months to <2 years,
4) >2 years  which will enable to correlate the infection with the degree of
immunosuppression the patient had received during that period.
AIMS & OBJECTIVES
1. To determine the prevalence of lower respiratory tract infections in post renal
transplant recipients and its association with risk factors,
2. To look for the type of organism causing pneumonia  and its relation with
duration of  transplant,
3. To determine the antibiotic susceptibility pattern of bacterial infections.
REVIEW OF LITERATURE
Organ transplantation is the transfer  of an organ from one person to another
or from one site to another site of the same person or a different person  in order to
replace the recipient's damaged or absent organ.
Types of transplant: Brenner @ Rector 80
Autograft:
It is the transplantation of organ to the same person. There will be no mounting
of immune response against the transplanted organ
Allograft:
It is the transplantation of organ between genetically  non identical members of
the same species i.e the  donor and the recipient. The immune system of the recipient
identifies the donor organ as foreign and mounts an immune response to destroy it.
Isograft:
It is the transplantation of organ between identical twins. Here the recipient's
body doesn't mount an immune response.
Xenograft:
It is the transplantation of organ between members of different species. There
is an  increased risk of non-compatibility, rejection, and disease carried in the tissue.
Based on the source of the donor , renal transplantation is classified as
1) Living donor renal transplant, which is further divided as
a)Living related
b)Living unrelated  based on the biological relationship between the donor and
the recipient.
2) Deceased /cadaveric donor renal transplant
Living Donor renal transplant:
In this type of transplant, the donor is an alive individual and he donates his
organ or its part to a recipient. In this type of transplantation , the graft survival and
function will be excellent and the rejection rate will be lower compared to the
deceased donor transplantation. Hence the immunosuppression used will be less
aggressive  and  the infection rate will be lower  in comparison with the deceased
organ transplantation. This difference is also seen between a living related and
unrelated donor renal transplants as the rejection rate will be lower in related donor
transplants.
Deceased Donor transplant:
Here the donor is a deceased person who is brain dead and  who are
maintained viable by ventilators. In this type of transplantation the graft survival and
function will be somewhat lower and the rejection rate will be higher compared to the
living donor transplantation. Hence the immunosuppression used will be more
aggressive  and  the infection rate will be higher  in comparison with the living organ
transplantation.
Classification of immunosuppressive drugs:
1. Induction therapy,
2. Maintenance therapy,
3. Anti rejection therapy.
Induction therapy:
Induction therapy is treatment with a biological agent either a biological agent
either a lymphocyte depleting agent or an interleukin 2 receptor antagonist given
before, at the time of or immediately after  transplantation. It depletes or modulates T
cell responses at the time of antigen presentation. It increases immunosuppressive
efficacy by preventing acute rejection or by enabling reduction of other components of
regimen like calcineurin inhibitors or corticosteroids.
Protein drugs:
Depleting antibodies (against T cells, B cells, or both)
 Polyclonal antibody: horse or rabbit antithymocyte globulin
 Mouse monoclonal anti-CD3 antibody (muromonab-CD3)
 Humanized monoclonal anti CD-52 antibody (alemtuzumab)
 B-cell-depleting monoclonal anti-CD-20 antibody (rituximab)
 Nondepleting antibodies and fusion proteins
 Humanized or chimeric monoclonal anti-CD25 antibody (daclizumab,
basiliximab)
 Fusion protein with natural binding properties: CTLA4-Ig (Belatacept)
Intravenous gammaglobulin
C5 inhibitor
Eculizumab
Protease inhibitor
Bortezomib
Maintenance immunosuppressive therapy:
It is a long term treatment to prevent acute rejection and deterioration of graft
function. The therapy is started before or at the time of transplant and the initial
medication may or may not be used with induction therapy. Maintenance
immunosuppressive drugs are used in combination to minimise the toxicity that is
associated with each drug. Since the risk of acute rejection is highest in the first three
months after transplant, higher doses are used during this time and the dose of these
drugs are reduced thereafter. The maintenance immunosuppression is used for all
patients lifelong.
Glucocorticoids
Small-molecule drugs
Immunophilin-binding drugs
Calcineurin inhibitors
Cyclophilin-binding drugs: cyclosporine
FKB12-binding drugs: tacrolimus, modified release tacrolimus
Target-of-rapamycin inhibitors: sirolimus, everolimus
Inhibitors of nucleotide synthesis
 Purine synthesis (IMDH) inhibitors
 Mycophenolate mofetil
 Enteric-coated mycophenolic acid (EC-MFS)
 Mizoribine (MZR)
 Pyrimidine synthesis (DHODH) inhibitors
 Leflunomide
 FK778
 Antimetabolites: azathioprine (Aza)
 Sphingosine-1-phosphate-receptor antagonists: FTY720
Protein drugs
Depleting antibodies (against T cells, B cells, or both)
 Polyclonal antibody: horse or rabbit antithymocyte globulin
 Mouse monoclonal anti-CD3 antibody (muromonab-CD3)
 Humanized monoclonal anti CD-52 antibody (alemtuzumab)
 B-cell-depleting monoclonal anti-CD-20 antibody (rituximab)
Nondepleting antibodies and fusion proteins
 Humanized or chimeric monoclonal anti-CD25 antibody (daclizumab,
basiliximab)
 Fusion protein with natural binding properties: CTLA4-Ig (Belatacept)
Intravenous gammaglobulin
C5 inhibitor
Eculizumab
Protease inhibitor
Bortezomib
Antirejection therapy: (Acute rejection )
These agents are used to treat acute rejection. There are two types of acute organ
rejection.
a) Cell mediated rejection
b) Antibody mediated rejection
Agents used to treat acute rejection are steroid pulse, antithymocyte globulin,
muromonab CD3
Immunosuppressive regimen protocol Stanley Medical College:
Induction agent:
The immunosuppressive regimen starts with an induction agent for deceased
and spousal transplants (high risk transplants) with either a lymphocyte depleting
agent Anti thymocyte globulin in a single dose of 1.5mg/kg in an infusion for 4-6hrs
perioperatively  or a T cell non depleting monoclonal antibody against IL2 receptor
Basiliximab ,20mg infusion for 30 minutes on day 0 and day 4. Live related renal
transplants and patients with risk of sepsis in high risk transplants are not given
induction.
Intraoperatively 1gm pulse methyl prednisolone is given intravenously before
clamp release of the renal vessels .
Maintenance therapy:
A triple immunosuppressive regimen is started from day 0 for maintenance
therapy and given lifelong. It includes Tacrolimus (0.1mg/kg/day) and its trough level
in blood is maintained at 8-10 ng/ml upto 30 days. Then the dose is gradually tapered
to maintain  at 7-8ng/ml for the first three months and at 6-7ng/ml for the next three
months (2nd month- 7th month).Then the dosage is adjusted to maintain a trough level
of 3-5ng/ml life time.
The second drug is Mycophenolate Mofetil. It is given in a dosage of 1gm/day
(<50 kgs), 1.25gm/day (50-60kgs) or 1.5g/day(>60kgs) lifelong.
The third drug is oral prednisolone  given in a dose of 0.5mg/kg/day up to 20
days .Then it is tapered to 20mg and given for next 15 days and tapered to 15mg for
next 15 days. Then  the drug is given in a dosage of 7.5mg-10mg  according to the
body weight lifelong.
The dosage is not fixed and is individualised according to the therapeutic effect
needed and for reducing the adverse affect.
Anti rejection therapy:
For patients with rejection, low dose intravenous pulse methyl prednisolone
(250mg-500mg) is given for 3-5 days.
Prophylaxis for Pneumocystis carinii:
Cotrimoxazole is given life long
Prophylaxis for CMV:
Valgancyclovir  450mg od is given for 3 months for patients who were given
Anti Thymocyte Globulin.
Effects of  immunosuppressive agents:
Immunosuppressive agents causes 3 major effects
1) The intended therapeutic effect of suppressing rejection
2) The deleterious acquired immunodeficiency that the host sustains leading to
increased risk of infection or malignancy
3) The direct or indirect toxicity to the tissues
Infection and immunosuppression:
The immunosuppressive agents used in transplantation targets single or
multiple sites of the immune system and helps in preventing rejection. So they play a
double edged sword impairing the recipient's immune response thereby predisposing
them to a variety of pathogens. All the major immune defence mechanism including
the anatomical barrier, innate immunity, acquired immunity is breached resulting in
opportunistic infection. They cause drug induced anti proliferative capacity leading
anti proliferative capacity leading to erosion of mucosal barrier, transient cytopenia,
hyperglycemia,  uremia, malnutrition, use of invasive devices leading to trauma,
colonisation , infection.
While surgical procedures are well established, the field of transplantation
continues to explore and experience innovations in immunosuppressive therapy with
goals of improving outcomes and in pursuit of tolerance. 34The positive effects of the
immunosuppressive agents, obligatory for the prevention of organ rejection, have been
tempered by the negative effects of these same therapies, leading to various infections
that range in both frequency and severity.35 Newer immunomodulating agents have
been developed, increasing the number of therapies that prevent organ rejection.
However, this has simultaneously created newer unwanted opportunities for pathogens
to cause infectious complications.36,37
Infection in post renal transplant recipients:
Urinary tract infections were the most common infection (23.6%) 13followed
by pulmonary infections in case of renal transplant recipients.
Incidence of Pneumonia in renal transplant recipients:
The incidence of  pneumonia   is highest in lung transplant recipients  of about
72% 1 followed by heart (17-28%) 2,3,4 and liver (8-23%) 5,6 and kidney (2.9-30%)
transplant recipients 7,8,9.The incidence of pulmonary infection is lowest in kidney
transplant recipients, reflecting the less rigorous surgical procedure required to
implant the allograft and the decreased level of immunosuppression required to
maintain it.10
Perioperative complications: renal transplantation.
Renal transplantation is done with low perioperative pulmonary complications
due to the use of a lower abdominal incision and  relatively  a better health of the
transplant  recipients 11,12. Most of the patients are extubated in the operating room.
Pulmonary edema is the most common non infectious pulmonary complication due to
impairment of salt and water excretion in the setting of early allograft dysfunction or
rejection. Risk of thromboembolic events due  to pelvic vein manipulation during
surgery may occur11.
Gender difference among renal transplant recipients with LRTI:
The percentage of  pulmonary infection was more in males about 83.4%
compared to females16.5% according to a study conducted by R Ram, KV Dakshina
Murty, N Prasad Department of Nephrology, Nizam’s Institute of Medical Sciences,
Punjagutta, Hyderabad13
Age group:
According to a study conducted in Hyderabad , most of the patients fall in the
age group of 20-39 years(53.8%) and this age group had maximum number of
infections followed by 40-59 years age group (34.3%) , 0-19 years(8.7%)  and >60
years group(1.7%) 13
Spectrum of  infections in renal transplant recipients:
Bacterial pneumonia in renal transplant recipients:
Bacteria  is the most common cause of lower respiratory tract infections in solid
organ transplant recipients 21,22,23,24. It is more common in cardiac (15%) transplants
followed by  liver (9%) and kidney (4-6% ) transplant recipients .In  liver and kidney
transplant recipients the mortality  due to pneumonia was  21% and 35%, respectively.
25
.
Infection by nosocomial pathogens constitutes most of the infection in the
initial perioperative period which includes Pseudomonas aeruginosa,
Acinetobacter species, and Staphylococcus aureus , Escheria coli, Klebsiella species .
The risk for nosocomial pneumonia is increased if the duration of mechanical
ventilation is prolonged following transplant After the initial post-transplant period,
community acquired pathogens including Haemophilus influenza, Streptococcus
pneumonia, and Legionella species predominate. With the use of trimethoprim-
sulfamethoxazole for the prophylaxis of pnemocystis carinii, the incidence
of Nocardia pneumonia  is very much reduced. Nosocomial and community acquired
pneumonia  constitutes  about 58% and 8% mortality respectively. Mechanical
ventilation and nosocomial infection are increased risk factors for morality associated
with pneumonia 25
Pulmonary tuberculosis in renal transplant recipients:
Incidence of tuberculosis in SOT:
The incidence of M. tuberculosis in solid organ transplant recipients is 30 to
100-times higher than in the general population.  In endemic areas  the incidence of
mycobacterium tuberculosis in solid organ transplants is 15% 25.The incidence of
tuberculosis in renal allograft recipient is 12.3% 41
Median time to develop TB:
The median time to develop tuberculosis is 20 months  as per the study
conducted by JIA Liu and his colleagues.38 A global review on TB estimated the
median time for onset at nine months post transplantation.39Immunosuppression with
tacrolimus or mycophenolate has  been associated with the development of TB earlier
in the post transplantation period and at a higher frequency within 6 months .40Lung
is the most common organ affected(62.2% ie 1.6% cases of pulmonary tuberculosis
among the transplant recipients).38.Majority of tuberculosis occurs within one year
42,43,44 of post transplant.
Risk factors for tuberculosis:
45,46,49
Diabetes and Tuberculosis:
According to a study conducted in Christian Medical College Vellore, diabetes
mellitus, PTDM ,chronic liver disease, and the occurrence of other coexisting
infections such as deep mycoses, CMV, PCP, Nocardia are important risk factors for
post transplant Tuberculosis in renal transplant recipients.48
HCV and Tuberculosis:
According to a study conducted in University hospital Spain, Hepatitis C virus
infection  is an important risk for tuberculosis in post renal transplant recipients. The
patients with HCV infection had higher percentage of tuberculosis infection than in
the controls.47
Reactivation of  latent infection is the most common cause of  infection and
primary infection and transmission from the donor allograft also occurs. In
tuberculosis infection the most common organ affected  are the lungs. Though fever is
the common presentation it is not universally present. Focal infiltrate, miliary pattern,
cavitary disease, diffuse infiltrates, and pleural effusions are the radiographic
presentations .25
Fungal pneumonia in renal transplant recipients:
Incidence of fungal pneumonia:
Two contemporary studies in liver and kidney transplant recipients found the
incidence of fungal pneumonia (not including pneumocystis jirovecii) ranges  between
8 and 17% 22. Another study conclude that pulmonary infections in kidney transplant
recipients  is about 1 to 4% 21,27. Even though the occurrence of fungal pneumonia is
lower than bacterial pneumonia in transplant recipients, fungal pneumonia carries a
higher mortality rate  of 80-100% when disease becomes invasive 28, 29.
Risk factors causing fungal pneumonia in renal transplant recipients:
Invasive fungal infection occurs in renal transplant recipients due to various risk
factors which include the host and environmental factors:
 renal failure,
 post operative complications,
 frequent bacterial infection,
 recurrent intensified  immunosuppression
 people in older age group, 28
 environmental exposure,
 colonization with pathogenic fungi,
 use of antifungal prophylaxis,
 net state of immunosuppression which includes anti rejection therapies,
breaches in mucocutaneous barriers, leukopenia, comorbid conditions (e.g.,
malnutrition, cirrhosis, diabetes mellitus and hypogammaglobulinemia) and
chronic viral infections (e.g., CMV, HCV, HBV and HIV) 31
Organisms causing fungal infection:
Candida (35-91%) or Aspergillus species (9-52%)  is the most common fungal
infection affecting lungs  in transplant recipients.29
Candida:
According to the  study conducted by Pugliese F and his colleagues , most of
the nosocomial fungal colonization or infection in solid organ transplant patients is
caused by Candida spp (98% ) in a transplant ICU 30. Candidal infection was
associated with a longer stay in the intensive care unit (30 vs. 5 days) and increased
mortality (35% vs. 3.5%) than patients without Candida infection.
Aspergillus spp:
Aspergillus sp. is a saprophytic  fungal organism . It causes more serious
infection and increased mortality than Candida sp. In a case control study conducted
by Gavalda J and his colleagues, the overall incidence of invasive  Aspergillus fungal
infection  was found to be 1.4% in over 11,000 patients and is about  0.2% in renal
transplant recipients 28. The mortality rate  for invasive Aspergillosis patients was
about 54% . Most  of the invasive Aspergillosis cases occurred within the first 90
days. The risk factors associated with earlier infection  were complicated
postoperative course, recurrent bacterial infections or CMV disease  and renal failure.
Patients who developed later disease were older and they had intense
immunosuppression  and renal failure.
Other organisms:
Other opportunistic fungal infections which causes pneumonia
include scedosporium, fusarium, cladosporium, rhizopus, and mucor species 60. The
mortality was about 55% for non aspergillus mycelial infection. The mortality rate
was 80-100% in patients with zygomycosis (rhizopus andmucor species) or non-
aspergillus hyalohyphomycosis (scedosporium
Mucormycosis:
In solid organ transplantation Mucormycosis causes  invasive fungal infections
in a small proportion of patients. But it causes a very high mortality rate. The range of
incidence of mucormycosis is about  0.2%– 1.2% in renal transplant recipients. .In a
retrospective study  conducted by Singh N , neutropenia, acidosis with and without
hyperglycemia and deferoxamine (DFO) use were absent in solid organ transplant
recipients 75 but all patients were under  chronic immunosuppression, with high doses
of systemic corticosteroids and  dissemination to distant organs has occurred after
rejection and its treatment. In a prospective, matched, case-controlled study of
mucormycosis in  solid organ transplant  recipient patients, renal failure, diabetes
mellitus, and prior voriconazole and/or caspofungin were associated with an
increased risk of mucormycosis 76. But tacrolimus  was associated with a decreased
risk for mucormycosis.. Median  time to develop mucormycosis was about 5.7
months.
Diabetes Mellitus and Ketoacidosis- important risk factors for mucormycosis. 32
In many of the studies, diabetes mellitus is reported  as a predisposing factor
for the development of mucormycosis( 36%–88% ) 63, 64–73. Patients with uncontrolled
hyperglycemia, particularly those with ketoacidosis, are more prone to develop
mucormycosis. 69, 70,74. In some patients, Mucormycosis may be the first manifestation
with undiagnosed diabetes mellitus 72, but it is hardly noted in those patients with
diabetes under control 62. Type 1, type 2, and secondary diabetes mellitus are all
reportedly risk factors for mucormycosis 73.
Endemic dimorphic Fungus:
Dimorphic fungi such as Coccidioides immitis, histoplasma capsulatum and
blastomyces dermatitidis have also been reported77. Patients with blastomycosis
frequently present with respiratory failure (78%) but fortunately the incidence of
blastomycosis in solid organ transplant recipients is only 0.14% which is lower than
that of histoplasmosis (0.4-2.1%) or coccidioidomycosis (0.59-8.7%)
77
. Cryptococcus accounts for 3% of invasive fungal infections in SOT recipients but
is associated with a mortality of up to 40% 78
Pneumocystis jirovecii
Before the use of trimethoprim-sulfamethoxazole (TMP-SMX) , the
incidence of pneumocystis jirovecii (formerly pneumocystis carinii) pneumonia (PCP)
infection ranged between 15% and 88% in heart-lung recipients and 0.6 to 11.5% in
renal transplant patients .Infection usually develops between three and 6 months post
transplant when the  immunosuppression is maximum. Recent evidence suggest that
rituximab use for treatment of acute humoral rejection had lead to PCP pneumonia in
renal transplant recipients.22
Immunosuppressive regimens:
Induction agents:
T cell depleting agent: Anti thymocyte globulin:.
Mechanism of Action
Anti thymocyte globulin is a polyclonal antibody which is produced by the
infusion of human T cells into horse or rabbit . It causes dose dependent depletion of
T-cells and it also has effect on B cells, natural killer cells, regulatory T cells and
dendritic cells. The degree of  depletion of T-cells  is dependent on the total dose of
the drug administered and also on  the duration the therapy is being given. Usually the
course of therapy is 3-5 days and it may range from 1-10 days 50
Side Effects
Anti thymocyte globulin can cause infusion related symptoms like fever,
hypotension, rashes, chills. It also causes CHF, serum sickness, eosinophilia  or
leucopenia, thrombocytopenia. 51,52,53.
Duration of Effect
Rabbit- Anti thymocyte globulin has a long half life of about 30 days but CD3
lymphopenia may last up to one year. Human- Anti thymocyte globulin has a less
intense CD3 suppression and has  and a shorter duration of effect and lymphopenia
usually resolves  in about 14 days) 54.
General Infectious Disease Issues
Several studies  have compared the effect of  R-ATG with H-ATG. In one
study, 56% of patients who were treated with R-ATG developed infection during the
first year after transplant as compared to 75% with H-ATG. In a study conducted by
Cinacio G and his colleagues patients received ATG is  compared with patients who
received alemtuzumab or daclizumab for induction during renal transplantation. It
showed a infection rate of 27% in each group with 3 cases of Cytomegalovirus and 1
case of BK virus nephropathy 55.
Bacterial Infection
The effect of Anti thymocyte globulin on bacterial infections is not clearly
defined in any of the studies. In renal transplant recipients there is increase in
incidence of urinary tract infections and wound infections. In a  study conducted by
Midtvedt K and his colleagues ATG has been associated with increased incidence  of
pneumonia, bacteremia or sepsis 56. Studies conducted on  lymphocyte depleting
therapy (including both alemtuzumab and anti-thymocyte globulin) have showed no
association with Nocardia infections whereas high dose steroids, Cytomegalovirus
infection and high calcineurin inhibitor levels were associated with Nocardia
infection57.
Fungal Infections
Generally ATG induction in renal transplants  does not lead to any  increase in
incidence of fungal infection. Anti-rejection utilization does  There is also no increase
in  risk  if ATG is used as rejection therapy. But ATG causes increased risk for
Pneumocystis carinii pneumonia when no prophylaxis has been given. False
positive Histoplasma urine antigens have been identified in those who have received
R-ATG. Cryptococcosis was associated when two  doses of R-ATG is given but not
when1 dose is given for renal ransplants.  The median time for diagnosis was 255 days
and the death rate was 14.2% 58.  Anti thymocyte globulin is not associated with
zygomycetes infection while renal failure, diabetes, prior voriconazole or caspofungin
use were. Tacrolimus lowered the risk of zygomycosis infection 59.
L-2 receptor antagonist (basiliximab)
Mechanism of Action
Basiliximab (Simulect) is a chimeric murine-human monoclonal antibody that
binds selectively to the alpha chain (CD25) of the IL-2 receptor.. IL-2 is a
leukocytotrophic hormone that is instrumental in the body's natural response to
microbial infection and cannot discriminate between foreign and self. CD25 is a type I
transmembrane protein present on activated T-cells, activated B-cells, some
thymocytes, myeloid precursors and oligodendrocytes. CD25 associates with CD122
to for a high affinity receptor for IL-2. Resting lymphocytes are not targeted by IL-2
receptor antagonists. CD25 participates in lymphocyte differentiation, activation, and
proliferation. At this time, these medications are used mostly for solid organ induction
in recipients who are low risk for rejection.
Duration of Effect:
The half life of basiliximab is long about  13.4 days in adults and for about 9.4
days in children. Basiliximab completely saturates the  interleukin-2 receptor for a
period of about 4-6 weeks in adult renal transplant recipients and for about 42 days in
pediatric recipients.
Infection and Basiliximab:
A major advantage  of basliliximab is the decreased risk of infection when
compared to  T-cell depleting agents. According to the various studies conducted,
there is no increase noted in the incidence of CMV, fungal and bacterial infections
when compared to placebo or other therapies for induction 14.When basiliximab has
been  used for rejection there was increase in incidence of CMV infection  when
compared to ATG (17.5% v 7.8%) .But this is not proven in other studies. In clinical
trials leading to basiliximab’s approval, the overall incidence of cytomegalovirus
infection was similar in basiliximab- and placebo-treated patients (15% vs. 17%)
receiving a dual- or triple-immunosuppression regimen. When basiliximab is given to
patients receiving a triple-immunosuppression regimen, the cytomegalovirus infection
was higher when compared to patients  treated with placebo (11% vs. 5%) . The risk
of infections, serious infections, and infectious organisms were same in the both
basiliximab- and placebo treated patients  among dual- and triple-therapy received
patients.14
Comparison between basiliximab and antithymocyte globulin regarding
infection:
A study was conducted by  Christian Medical College, Vellore from January
2006 to December 2008 15 in consecutive living related renal allograft recipients
undergoing kidney transplantation between the two induction groups. One group
received Basiliximab and  the other received ATG. The incidence of  tuberculosis
(1.8, 0.0 & 7.6%: p=0.04*) and BK virus infection (0, 4.8 & 6.7%: p=0.001*) were
less in the basiliximab group. The  incidence of pulmonary infections, bacterial sepsis
(Non UTI), systemic mycosis, CMV disease and herpes virus infections were also less
in basiliximab groups . Patients who received ATG (but not basiliximab) had a higher
incidence of new onset diabetes after transplantation (21.4, 38.1 & 12.4%: p=0.004#)
and leucopenia .
A study conducted by chinese from Feb. 2007 to Jul. 2012 compared the
safety between  lymphocytes scavenger and IL-2 receptor blocking agent, in living
kidney transplant recipients. There was no significant difference in the incidence of
infection and the survival rate of patient/allograft (P>0.05) within one year after
transplantation. Both the inducing agents  had reduced  the incidence of acute
rejection within one year but did not increase the incidence of infection.16
In a study conducted by Brennan DC and his colleagues in renal transplant
recipients, it was concluded that  patients receiving anti thymocyte globulin had a
higher incidence of infection (85.8%) when compared to Basiliximab (75.2%)
received patients P=0.03. But the incidence of cytomegalovirus(7.8% )is lower in
ATG group compared to Basiliximab group (17.5%)18
In another study conducted by Carlsen J and his colleagues in cardiac
transplant patients who received induction agents , it was concluded that the bacterial
infections were significantly higher in ATG group than in the Daclizumab group
(p=0.05)19
In a 6 month prospective study conducted by Mattei MF and his colleagues in
cardiac transplant patients , infection death were less frequent in basiliximab group
compared to ATG group (0 of 38 vs 6 of 42, p=0.027) 20
Calcineurin inhibitors:14
Calcineurin inhibitors was first introduced in 1980s . It includes cyclosporine A
and tacrolimus (FK506).  Calcineurin inhibitors have become the major maintenance
immunosuppressive drug. Tacrolimus  binds  to FK506-binding proteins 12 (FKBP12)
and inhibits calcineurin activity  and production of interleukin-2 (IL-2) needed  for T
cell proliferation is blocked, leading  to decreased T-cell response for alloantigens.
Tacrolimus is 100 times more potent than cyclosporine .
Side effects:
The side effects to tacrolimus are nephrotoxocity, hyperkalemia,
hypomagnesemia posttransplant diabetes, neurotoxicity (such as headache, seizure,
posterior leukoencephalopathy, and hand tremor,  gastrointestinal symptoms
(diarrhoea  and abdominal discomfort), alopecia, hyperuricemia and exacerbation of
gout occur .Close monitoring of tacrolimus levels is essential to avoid drug overdose
or under dosing due to drug-drug interaction.
Infection and Tacrolimus:
Mycophenolate mofetil causes a significant increase in  incidence of BK virus
nephropathy in renal transplant recipients .Calcineurin inhibitors are believed to have
antifungal attributes . Calcineurin is required for growth of C. neoformans at 37oC but
not at 24oC.  Tacrolimus demonstrated greater activities against C. neoformans than
cyclosporine. Calcineurin inhibitors also have antifungal activity against A.
fumigatus . Additionally, calcineurin inhibitors enhance the activities of antifungal
agents.
Mycophenolate Mofetil (MMF):14
MMF which is one of the  triple immunosuppressive drugs is  a potent inhibitor
of inosine-5’-monophosphate dehydrogenase. It  is  metabolized to mycophenolic acid
. and  inhibits de novo synthesis of guonosine which results in a lack of
deoxyguanosine triphosphate so that  DNA synthesis is suppressed  . Decreased DNA
synthesis leads to decreased proliferation of T and B lymphocytes .The cells affected
by MMF are the activated T lymphocytes, cytotoxic T cells, B lymphocytes, and
immunoglobulin .It is  used as a calcineurin inhibitors- or steroid-sparing agent.
Side effects:
Anemia or leukopenia and gastrointestinal effects(mainly diarrhoea) are most
common side effects in patients receiving MMF. These symptoms are usually dose-
related, and may be improved with dose reduction.
Infection and MMF:
CMV disease is the infection most commonly associated with receipt of MMF.
A higher incidence of CMV disease in patients receiving MMF at a dose of either
3g/day or 2g/day  was note than Azathioprine based regimen. Nevertheless, in a
review and meta-analysis of calcineurin inhibitor sparing with MMF in 19 randomized
controlled trials with cyclosporine as the comparator in most studies, the incidence of
infections and CMV disease/infection rates did not differ in two groups . Additionally,
patients receiving MMF with or without tacrolimus were more likely to have BK virus
viremia or nephropathy . Varicella-zoster virus has also been reported to occur more
commonly in MMF recipients.
MMF has shown antimicrobial activities against various pathogens in in
vitro or animal models, including Dengue virus, hepatitis C virus, hepatitis B
virus, Pneumocystis jirovecii, Coxsachie virus B3, West Nile virus, yellow fever
virus, and human immunodeficiency virus (HIV). Only its activity
against Pneumocystis pneumonia (PCP) in liver transplant recipients is proved
clinically.
Infection in transplant recipients  based on time since transplant:33
"Infection in transplant recipients based on time since transplant" is the idea
first described by Jay A Fishman and Robert H. Rubin in their study "Infection in
organ transplant recipients".
Gist of the study:
The risk of infection in  solid organ transplant recipients depends primarily on
two major factors
 Intensity of exposure to potential pathogens(Epidemiologic exposure)
 Combined effect of all the factors which contributes to a patient's
susceptibility to infection (net state of immunosuppression)
Concept:
a)Immune status of the patient is normal- Infection has occurred
Increased environmental exposure / the level of immunosuppression is   greater than
was thought
b)Minimal environmental exposure-infection has occurred
Level of immunosuppression was high
Epidemiologic exposure:
This can occur in hospital  or community which is called nosocomial or
community acquired respectively. Nosocomial pathogens are mostly pseudomonas,
methicillin resistant staph aureus, vancomycin resistant enterococci, candida etc.
Community acquired pathogens are mostly organisms like respiratory viruses, food
borne pathogens like salmonella, Listeria monocytogenes, Campylobacter jejuni,
tuberculosis, dimorphic fungus etc
Net state of immunosuppression: It is due to
 Immunosuppressive therapy: dose, duration, and temporal sequence
 Underlying immune deficiency: autoimmune disease, functional immune
deficits
 Integrity of the mucocutaneous barrier: catheters, epithelial surfaces
 Devitalized tissue, fluid collections
 Neutropenia, lymphopenia
 Metabolic conditions
 Uremia
 Malnutrition
 Diabetes
 Alcoholism with cirrhosis
 Infection with immunomodulating viruses
 Cytomegalovirus
 Epstein–Barr virus
 Hepatitis B and C viruses
 Human immunodeficiency virus
Time table of infection after transplant according to Rubin:
Infection in first month after transplantation:
Most of the infections which occur during the period are nosocomially
acquired pathogens. Usually 90% of them are bacterial or candidal infection. Most of
the infections are surgical site infections, nosocomial  pneumonia, urinary tract
infections or infection related to vascular access devices. the important factors
determining such infections are the nature of operation, the surgical  skills, duration
of vascular access, drainage catheter, duration of intubation, presence of indwelling
stents, foreign bodies and presence of fluid collection and devitalised tissues. Due to
antimicrobial prophylaxis, the incidence is very much reduced.
Very rarely infection from the donor through the graft may get reactivated.
Opportunistic pathogens such as fungal infection and CMV is very rare during this
period even though the immunosuppression is maximum during this period. This is
because the net state of immunosuppression is determined by the sustained level of
immunosuppression the patient had rather than the dosage of the drug given during
that period.
Infection one to six months after transplantation:
During this period, the residual effects of earlier infection may persist and
newer infections may appear. The immunomodulatory viruses like CMV, EB virus,
HBV, HCV, HIV exert the primary effect during this period. These infections along
with sustained immunosuppression leads to patient's net state of immunosuppression
leading to opportunistic infections like  mycelial fungal infections, Pneumocystis
carinii ,dimorphic fungii etc.
More than 6 months after transplantation:
Three types of patients
Type 1: 80% patients have good allograft functions. Low level  of
immunosuppression received. Infections are similar to common people.
Type 2 : 10% patients have chronic infection with HBV, HCV, CMV, EBV or
have diabetes ,malignancy which may increase the risk of infection leading to
secondary infections .
Type 3 : 5-10% patients have recurrent rejection requiring increased
immunosupprression which results in opportunistic infections.
MATERIALS & METHODS
Type of study:
Both prospective and retrospective study
Place of Study & Period of Study:
Department of  Microbiology, Stanley Medical college,
Department of Nephrology, Stanley Medical college.
Study period:
September  2014 to August 2015.
Sample size and Inclusion criteria:
A total of 147 post renal transplant recipients who are followed as inpatients
and outpatients in the Department of Nephrology, Stanley Medical College were taken
for the  study. The details of lower respiratory tract infection that occurred previously
is collected from the patient's record and the newer samples were also collected and
processed from the patients with symptoms and signs of respiratory tract infection .
Ethical Consideration
Ethical and research clearance was obtained from the Ethical committee,
Stanley Medical College. Permission to conduct the study was sought from the
respective hospital department authorities. Informed consent was obtained from
the patients before enrolment in to the study.
Statistical Analysis
The collected data was analyzed with SPSS 21.0 version. To describe about the
data descriptive statistics frequency analysis, percentage analysis were used for
categorical variables and for continuous variables the mean and S.D were used. To
find the significance in categorical data Chi-Square test was used. The probability
value 0.05 is considered as significant level. To test the significance between two
proportions, z test for proportion is used.
SPECIMEN COLLECTION AND LABORATORY TESTING:
After obtaining proper history and consent, samples were collected from post
renal transplant patients with suspected lower respiratory tract infections.
Expectorated sputum:
The patient was educated about the difference between sputum and oral
secretions.  The patient was asked to rinse the mouth with distilled water or normal
saline (sterile) and then expectorate deep cough sputum directly into a sterile screw-
cap collection cup or sterile dry container. The patient was instructed not to
expectorate saliva or post nasal discharge into the container.
Induced sputum:
Using a wet tooth brush and sterile water or saline the patient was
instructed to brush the buccal mucosa, tongue, and gums for 5 to 10 minutes prior to
the procedure. Tooth paste should not be used. Patient was asked to rinse the mouth
with sterile water or saline. Using an ultrasonic nebuliser, the patient was asked to
inhale 20-30 ml of 3% NaCl. The induced sputum was collected in a sterile leak proof
container.
Bronchoalveolar washing or BAL sample:
The BAL sample was obtained from the distal respiratory bronchioles and
alveoli. Bronchial washings sample was obtained from the major airways.
The bronchoscope was passed transorally or transnasally. Inject sterile
nonbacteriostatic 0.85%  NaCl from a syringe through a biopsy channel of the
bronchoscope. BAL sample was collected wedging the tip of bronchoscope into an
airway lumen and instilling a large volume of sterile,   nonbacteriostatic saline. The
sample obtained contains secretions distal to the bronchioles and alveoli. The
recovered specimen is suctioned into a sterile container.
Transbronchial biopsy samples:
Biopsy sample was obtained through the biopsy channel of the bronchoscope
and transport in a sterile container with a small amount of non bacteriostatic saline.
Specimen transport:
The collected lower respiratory tract specimen was transported immediately to
the laboratory and processed according to the standard microbiological procedure.
Blood collection:
About 12 ml of whole blood was collected by venepuncture by strict aseptic
technique . About 8ml of the blood was inoculated into biphasic broth ( Trypticase soy
agar with Brain heart infusion agar). 4ml of the blood was kept for pp65 antigen
detection of CMV.
Viral Studies:
PP65 antigen in polymorphonuclear leukocytes from peripheral blood for CMV
was done by giving the sample  to outside laboratory.
Processing of lower respiratory tract samples was done as below
Direct smear with gram's staining:
The thick purulent part of the sputum was taken and smeared on to a clean
glass slide about 2cm in breath and 1cm in width. The smear was then air dried and
heat fixed and was stained by gram staining technique.
The smear was mounted on the oil immersion microscope and was looked for
the presence of pus cells and bacteria and epithelial cells .
AFB staining:
The sputum obtained was first concentrated by modified Petroff's method  by
digestion and decontamination. Digestion was done by N- Acetyl-L-Cysteine (NALC)
and decontamination was done by 2% NaOH.
Digestion and decontamination procedure:
Preparation of N-Acetyl cysteine and alkali mixture:
50 ml of 2.94% trisodium citrate-3.H2O (0.1 M) was mixed with 50 ml of 4%
NaOH. Then 0.5g of NALC powder was added to this mixture. NALC was a
mucolytic agent. It does not have any bacteriocidal activity. It liquefies the mucus by
splitting the disulphide bridges. The mycobacteria are released from the mucus plug
on liquefaction.
A 50ml of plastic centrifuge was taken and equal volume of NALC and alkali
mixture is added to equal volume of the specimen. The screw cap is tightened. The
mixture is homogenised with a vortex mixer for 15- 20 seconds. Then the tube is
allowed to stand for 20 minutes at room temperature. The digestion time should not
exceed 20  minutes.
After 20 minutes, phosphate buffer(pH 6.8) was added up to the ring in the top
of the centrifuge tube and is mixed well. The specimen was centrifuged at 2000g for
15-20 minutes. After centrifugation, the supernatant was discarded into a splash proof
container containing phenolic disinfectant. A small quantity of phosphate buffer was
added and the sediment was resuspended with a Pasteur pipette.
Kinyoun's method of Acid fast staining:
A portion of the sediment was smeared on to a clean glass slide about 2cm
length and 1 cm breath with a sterile bacteriological loop or an applicator. The smear
was air dried and heat fixed.
Culture is onto Lowenstein and Jensen medium:
A portion of the sediment was streaked onto one two bottles of LJ medium for
the culture of Mycobacterium species and was maintained for eight weeks.
KOH mount:
A clean dry slide was take and a drop of KOH was placed on the slide . A loop
full of sputum was placed over the KOH and mixed well . A cover slip was placed
over the sputum and left for 2 minutes at room temperature. Then the slide was
mounted on low power and in high power for the presence of hyphal and other fungal
elements.
Culture onto bacterial culture media:
The sputum was cultured onto blood agar, chocolate agar and MacConkey
medium and incubated overnight at 37◦C. The next day the plates are looked for the
appearance of colony morphology, haemolysis, pigmentation, whether lactose or non
lactose fermenter. Then smear was done from the colonies on culture plate and
examined under oil immersion microscope. According to the smear results,
biochemical tests are done appropriately to find out the bacterial organisms and
antibiotic sensitivity tests are done by Kirby Bauer method.
Kirby bauer method:
Inoculum preparation
Inoculum was prepared by direct colony suspension method by taking four to
five well isolated colonies from 18-24 hours culture, in Mueller Hinton broth to
achieve a turbid suspension.
Inoculum standardization
The inoculum suspension was compared with 0.5 McFarlands standard
suspension by positioning the tube side by side against a white card containing several
horizontal black lines. The turbidity was compared by looking at the black lines
through the suspensions. Once standardized, the inoculum suspension was used within
15 minutes of preparation.
Procedure
After standardization of bacterial suspension, the suspension was vortexed to
make sure, it was well-mixed. Then by using a sterile swab, inoculation was done on
MacConkey agar and excess fluid was removed by pressing the swab against the side
of the test-tube .Swab was streaked evenly over the surface of the medium in three
directions; the plate was rotated approximately 60° for even distribution. With the
petridish lid in place, three to five minutes was allowed for the surface of the agar to
dry. Using sterile needle mounted in a holder, the appropriate discs were evenly
distributed on the inoculated plate. The discs were placed about 15mm from the edge
of the plate and not closer than about 25mm from disc to disc. Only six discs were
applied on a 90mm plate. Each disc was lightly pressed down to ensure its contact
with the agar. The plate was inverted and incubated at 35°C aerobically for full 24
hours.
Interpretation of results:
After incubation, the inhibition zone was measured to the nearest millimeter
using a ruler, under transmitted light. Inhibitory zone includes the diameter of the disc.
After measuring, the millimeter reading for each antimicrobial agent was compared
with that in the interpretive tables of he CLSI guidelines and results were interpreted
as either susceptible, intermediate or resistant.
Culture onto fungal culture media:
The sputum was streaked onto Sabourard's dextrose agar (two tubes) and
Potato dextrose agar (two tubes)for the growth of any fungus if present and was
maintained for eight weeks. One of the two tubes of each medium was maintained at
37◦C for the growth of yeast and the other tube was maintained at 25◦C for the growth
of hyphal forms.
OBSERVATION & RESULTS
Total post renal transplant recipient cases followed = 147
Total Lower respiratory tract infected patients = 40
MICROBIOLOGY PROFILE OF THE LOWER RESPIRATORY TRACT
INFECTED TRANSPLANT PATIENTS:
TYPE OF SAMPLES : (n=40)
Table 1
Type of sample Frequency
Sputum 28
Bronchoalveolar lavage 9
Lung biopsy specimen 3
Total 40
CULTURE RESULTS:
Table 2
Positive Negative
Bacterial culture 16 24
Fungal culture 5 25
Culture on LJ medium 12 28
BACTERIAL ORGANISMS ISOLATED:
Table 3
GRAM POSITIVE COCCI 2
GRAM NEGATIVE BACILLI 14
Table 4
ORGANISMS COUNT
Pseudomonas aeruginosa 6
Klebsiella spp 4
Staphylococcus aureus 2
Haemophillus influenza 1
Acinetobacter spp 1
Escherischia coli 1
Citrobacter spp 1
Total 16
Pseudomonas aeruginosa was the common bacterial organism isolated followed by
Klebsiella spp. Gram negative organisms were more common than gram positive
organisms.
FUNGUS IDENTIFICATION:
Total fungus identified=5
Table 5
KOH positive 2
Fungal culture positive 5
Biopsy suggestive 2
FUNGAL SPECIES IDENTIFIED:
Table 6
Mucor spp 2
Aspergillus fumigatus 2
Aspergillus nidulans 1
MYCOBACTERIAL IDENTIFICATION:
Total Mycobacteria identified=12
Table 7
POSITIVE NEGATIVE
ACID FAST STAINING 10 2
CULTURE ON LJ MEDIUM 12 0
ORGANISMS ISOLATED TIME SINCE TRANSPLANT:
Immediate postoperative period:
Table 8
ORGANISM COUNT SPECIFIC RESISTANCEPATTERN
BACTERIA
Pseudomonas spp 1 AMP C PRODUCER
Acinetobacter spp 1 CARBAPENAMASEPRODUCER
Staphylococcus aureus 1 METHICILLIN
RESISTANCE
Mostly multidrug resistant organisms are isolated.
<2 months:
Table 9
ORGANISM COUNT
BACTERIA
Pseudomonas spp 2
Klebsiella  spp 1
FUNGUS
Aspergillus 1
>2 months to 2years:
Table 10
ORGANISM COUNT
BACTERIA
Pseudomonas spp 2
Klebsiella spp 3
Escherichia coli 1
Citrobacter spp 1
Haemophillus spp 1
Mycobac. tuberculosis 6
FUNGUS
Aspergillus spp 2
Mucor spp 1
Community acquired organisms and opportunistic fungal organisms were isolated
>2 years:
Table 11
ORGANISM NO
BACTERIA
Pseudomonas 1
Staphylococcus aureus 1
Mycobac. tuberculosis 6
FUNGUS
Mucor spp 1
CMV 1
RESISTANCE PATTERN:
Table 12
ORGANISMS TOT COT AK CIP CEF-
3RD
G
CEFOX CARB
S R S R S R S R S R S R
N
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n
 F
er
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te
r 
G
N
B
S Pseudomonas
aeruginosa
6 IR 5 1 3 3 5 1 5 1 6 0
Acinetobacter
spp
1 0 1 0 1 0 1 0 1 - - 0 1
En
te
ro
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ae
Klebsiella spp 4 0 4 4 3 2 2 2 2 - - 4 0
Escherischia
coli
1 0 0 1 0 1 0 1 0 - - - -
Citrobacter spp 1 0 1 1 0 1 0 1 0 - - - -
O
th
er
G
N
B
s
Haemophilus
influenza
1 0 1 1 0 1 0 1 0 - - - -
G
PC
s
Staphylococcus
aureus
2 0 2 1 1 1 1 1 1 1 1 - -
IR=INTRINSIC RESISTANCE R=RESISTANCE S=SENSITIVE
COT=COTRIMOXAZOLE AK=AMIKACIN CEFOX=CEFOXITIN
CEF 3RD= 3RD GENERATION CEPHALOSPORIN CIP=CIPROFLOXACIN
CARB=CARBAPENAMASE
SPECIFIC RESISTANCE PATTERN:
Table 13
SPECIFIC RESISTANCE NO
Amp C Pseudomonas 1
ESBL Klebsiella spp 2
Carbapenamase producing Acinetobacter 1
MRSA 1
PATIENT PROFILE:
A total  of 147 post transplant cases were studied .
Out of which  males=87 and females=60.
Based on the donor type, live related transplant recipients =73, deceased
donor/cadaveric transplant recipients =58. Spousal transplant recipients=16.
A total of 20 patients had received Basiliximab , 9 patients had received ATG,
35 patients were diabetes.
40 had lower respiratory tract infection.
Among the lower respiratory tract infected patients, 7 had received
Basiliximab, 4 had received ATG, 9 had received intravenous pulse methyl
prednisolone for rejection episodes , 11 were diabetic, 8 had Tacrolimus level
>8ng/ml, 3 had HCV.
GENDER DIFFERENCE IN LOWER RESPIRATORY TRACT INFECTION
AMONG TRANSPLANT RECIPIENTS:
Table  14
GENDER
LRTI
TOTAL P-VALUEYES NO
MALE 34(39.08%) 53(60.92%) 87
<0.001FEMALE 6(10%) 54(90%) 60
TOTAL 40(27.21%) 107(72.79%) 147
Prevalence of  lower respiratory tract infection in renal transplant recipients is about
27.2%. The lower respiratory tract infection is more common in males (39.08%)
compared to  females(10%). The difference between the occurrence of lower
respiratory tract infection is statistically significant (P=<0.001)
Figure 1
AGE DISTRIBUTION  OF THE LOWER RESPIRATORY TRACT
INFECTION PATIENTS:
Table 15
AGE
INTERVAL
TOTAL LRTI
PATIENTS RATE
10-20 3 7.5%
21-30 17 42.5%
31-40 14 35%
41-50 6 15%
MEAN AGE=32
LRTI is more common in the age group between 21-40  (77.5%)
Figure 2
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LOWER RESPIRATORY TRACT INFECTION RATE AMONG TOTAL
RENAL TRANSPLANT RECIPIENTS BASED ON DONOR TYPE:
Table 16
DONOR
TYPE
LRTI
TOTAL P-VALUEYES NO
LIVE
RELATED 23(31.51%) 50(68.49%) 73
0.33SPOUSAL 2(12.5%) 14(87.5%) 16
CADAVER 15(25.86%) 43(74.14%) 58
TOTAL 40(27.21%) 107(72.79%) 147
Percentage of infections  more common in live related donor  transplant
recipients (31.5%) compared to  deceased donor transplants recipients(25.8%). There
is no statistical significance in the occurrence of lower respiratory infection between
the two (P=0.33)
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INFECTION RATE AMONG LOWER RESPIRATORY TRACT INFECTION
PATIENTS BASED ON DONOR TYPE:
Table 17
DONOR TYPE NO. OFINFECTED RATE
LIVE RELATED 23 57.5%
SPOUSAL 2 5%
CADAVER 15 37.5%
Among the lower respiratory infection patients , the highest occurrence is in
live related  transplants (57.5%) compared to deceased donor transplant(37.5%)
Figure 3
TYPES OF INFECTION AMONG THE RESPIRATORY TRACT INFECTION
PATIENTS:
Table 18
TYPES OF INFECTION NO. OFINFECTION
RATE  AMONG
TOTAL
ORGANISMS
BACTERIAL OTHER
THAN TB 16 35.55%
TUBERCULOSIS 12 26.66%
FUNGAL 5 11.11%
CMV 1 2.22%
OTHERS 11 24.44%
Among the organisms isolated , the highest is bacterial infection(35.55%)
followed by tuberculosis(26.66%), fungi (11.11%) respectively. In 24.44% of the
patients, no organisms were isolated.
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Figure 4
ORGANISM SPECIFIC INFECTION RATE :
Table 19
ORGANISMS NO.OFPATIENTS
RATE AMONG
LRTI
RATE AMONG
TOT  PTS
TB 12 30% 8.1%
FUNG.PNE 5 12.5% 3.4%
BACTER
PNEUM 16 40% 10.8%
CMV 1 2.5% 0.68%
Among the 40 LRTI patients, bacterial pneumonia contributes to about 40%,
tuberculosis contributes about 30% of the infection and fungus contributes about
12.55% of the infection.
Among the total  renal  transplants, the rate of bacterial pneumonia is 10.8%,
the rate of  pulmonary tuberculosis  is 8.16%, the rate of fungal pneumonia is 3.4%
and CMV is 0.68%
Figure 5
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RISK FACTORS FOR INFECTION ASSOCIATED WITH LOWER
RESPIRATORY TRACT INFECTED TRANSPLANTS:
Table 20
RISK FACTORS CADAVERIC LIVERELATED SPOUSAL
BASILIXIMAB
RECEIVED 5 - 2
ATG RECEIVED 3 1 -
PULSE S STEROIDS 2 7 -
DIABETIC 4 6 1
> 8 TACRO LEVEL 5 2 1
Cadaveric transplant recipients are associated with more risk factors than live related
transplants. But pulse steroids are more in live related transplants.
Figure 7
INDIVIDUAL RISK FACTORS FOR LOWER RESPIRATORY TRACT
INFECTION IN RENAL TANSPLANT RECIPIENTS:
Table 22
RISK FACTORS LRTI PTS
N(%)
BASILIXIMAB 7(17.5%)
ATG 4(10%)
PULSE STEROIDS 9(22.5%)
>8NG/ML TACRO 8(20%)
DM 11(27.5%)
HCV 3(7.5%)
Diabetes (27.5%) is the leading risk factor associated with  lower respiratory tract
infection patients (27.5%) , followed by pulse steroids (22.5%)  which is given for
rejection.
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ORGANISM SPECIFIC INFECTION RATE AMONG LOWER
RESPIRATORY TRACT INFECTED PATIENTS WITH RISK FACTORS:
Table 23
ORGANISMS ATG(N=4)
BASILI
(N=7)
PULSE
(N=9)
DIABETI
C
(N=11)
>8 ng/ml
TACRO
(N=8)
HCV
(N=3)
TB RATE 2(50%)a - 4(44.44%)a 4(36.36%)a 1(12.5%)a 1(33.33%)a
FUNG.PNEU
MO RATE -
2(28.57%)
a
1(11.11%)
a
4(36.36%)
* 1(12.5%)a 1(33.33%)a
BAC.PNEUM
O RATE
1(25%)
a 3(42.8%)a 6(66.66%)* 3(27.27%)a 4(50%)a -
CMV - - - 1(9.09%)a - -
a
= P>0.05, *=P<0.05
0.00% 5.00%
BASILIXIMAB
ATG
PULSE STEROIDS
>8ng/ml TACRO
DM
HCV
10.00%15.00%20.00%25.00%30.00%
17.50%
10%
22.50%
20.00%
27.50%
7.50%
In the association of specific risk factors with specific infection by proportion test,
only pulse steroids has statistical significance with bacterial pneumonia (P=0.03) and
diabetes has statistical significance with fungal pneumonia (P=0.002) and others are
not.
LOWER RESPIRATORY TRACT INFECTION RATE AMONG RENAL
TRANSPLANT RECIPIENTS WHO RECEIVED INDUCTION AGENTS:
Table 24
INDUCTION AGENTS BASILIXIMAB ATG P-VALUE
TOTAL CASES
FOLLOWED 20 9
0.68TOTAL  LRTI 7(P=0.8) 4(P=0.88)
LRTI RATE 35% 44.44%
The rate of lower respiratory tract infection occurred is more in ATG (44.44%) than
basiliximab (35%) but there is no statistical significance between the two (P=0.68).
Basiliximab (P=0.8) and ATG (P=0.88) has no statistical significance with lower
respiratory tract infection in renal transplant recipient patients.
ORGANISM SPECIFIC INFECTION RATE AMONG TOTAL DIABETIC
TRANSPLANT RECIPIENTS:
TOTAL DIABETICS  AMONG THE PATIENTS WITH RESPIRATORY TRACT
INFECTION= 11/40
Table 25
ORGANISM NO.OF DIABETICPATIENTS (N=35)
TB  RATE 4(11.4%)
FUNGAL PNEUM
RATE 4(11.4%)
BACTERIAL
PNEUM RATE 3(8.57%)
CMV 1(2.85%)
The rate of  lower respiratory tract infection has no statistical significance with
diabetes.(P=0.73). But fungal pneumonia has statistical significance with Diabetes
(P=0.002)
Figure 8
ORGANISM SPECIFIC INFECTION RATE AMONG DIABETIC  LRTI PTS:
Table 26
ORGANISMS HYPERGLYCEMIAUNDER CONTROL
UNCONTROLLED
HYPERGLYCEMIA RATE
TB RATE 60% 16.66% 36.36%
FUNGAL
PNEUM RATE 20% 66.66% 45.45%
BACTERIAL
PNEUM RATE 20% 33.33% 27.27%
CMV 0% 16.66% 9.09%
Fungal pneumonia (66.66%) and bacterial pneumonia (33.33%) is more common in
poorly controlled diabetes patients.
HCV with pulmonary TB= 8.33%
Fungus pneumonia in pulmnary TB patients= 8.33%
PART OF THE LUNG LOBES AFFECTED AMONG TUBERCULOSIS AND
FUNGAL PNEUMONIA:
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
TB  RATE FUNGAL PNEUM
RATE
11.40%
BACTERIAL
PNEUM RATE
CMV
11.40%
8.57%
2.85%
Table 27
LOBE AFFECTED TB RATE FUNGUS RATE
UPPER LOBE/ APICAL 7 58.33% 4 80%
MIDDLE LOBE 1 8.33% 0 0%
LOWER LOBE 3 25% 1 20%
PEURAL EFFUSION 2 16.66%
MEDIASTINAL
LYMPHADENOPATHY 1 8.33%
In both the fungal pneumonia (80%)  and  pulmonary tuberculosis (58.33), upper lobe
of the lung is most commonly affected.
TYPE OF FUNGUS ISOLATED:
Table 26
FUNGUS NO OFPATIENTS RATE
MORTALITY
RATE
MUCOR 2 40% 0%
ASPERGILLUS 3 60% 66.66%
FUNGUS WITH BACTERIAL  INFECTION=2/5
TB+ FUNGUS= 1/5
Aspergillus and mucor are the species causing fungal pneumonia. The mortality rate is
66.66%
>8NG/ML TACROLIMUS LEVEL  AND  SPECTRUM OF ORGANISMS
TOTAL LRTI PATIENTS ON TACROLIMUS=35
TACRO LEVEL KNOWN=32 PTS
Table 27
TACRO
LEVEL BACTERIA TUBERCULOSIS FUNGUS
NO
ORG TOTAL
>8-10 2 0 0 0 2
>10-15 1 0 0 1 2
>15 1 1 1 1 3
7 patients had tacrolimus level more than 8ng/ml in our study.
>8NG/ML TACROLIMUS LEVEL  AND  SPECTRUM OF ORGANISMS
Figure 9
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INFECTION RATE AMONG LOWER RESPIRATORY TRACT INFECTION
PATIENTS BASED ON TIME SINCE TRANSPLANT:
TOTAL CASES=40
Table 28
TIME SINCE TRANSPLANT NO OF
CASES
INFECTION
RATE
IMMEDIATE POST OP(7 DAYS) 7 17.5%
<  2 MONTHS 5 12.5%
>2MONTHS- 2 YEARS 16 40%
>2 YEARS 12 30%
The highest rate of LRTI occurs in the period between >2months-2years  (40%)
followed by >2 years (30%) post transplant.
Figure 10
OCCURENCE OF LOWER RESPIRATORY TRACT INFECTION TIME
SINCE TRANSPLANT BASED ON DONOR TYPE:
Table 29
DONOR
TYPE
IMMED
POST OP
<2MONTH
S
>2MONTHS-2YEARS >2 YEARS
>2M- 1Y >1Y-2Y
CADAVER 57.14% 60% 62.5% 12.5% 16.66%
LIVE
RELATED
42.85% 20% 37.5% 75% 83.33%
SPOUSAL 0 20% 0 12.5% 0
12, 30%
IMMEDIATE POST OP(7 DAYS)
>2MONTHS- 2 YEARS
7, 17%
5, 13%
16, 40%
<  2 MONTHS
>2 YEARS
Up to 1 year time since transplant, lower respiratory infection is more common in
cadaveric transplant recipients (60%). After 1 year , it is common in live related
transplant recipients (80%).
SPECTRUM OF ORGANISMS CAUSING LOWER RESPIRATORY TRACT
INFECTION TIME SINCE TRANSPLANT :
Table 30
INTERVAL BACTERIAL TUBERCULOSIS FUNGAL NO ORG
ISOLATED
IMMEDIATE
POST OP(7
DAYS)
3 0 0 4
<2 MONTHS 4 1 1 2
>2 MONTHS -
2YEARS
7 5 3 3
>2 YEARS 2 6 1 2
TOTAL PTS 16 12 5 11
57.14% 60% 62.50%
12.50% 16.66%
42.85%
20%
37.50%
75%
83.33%
20%
12.50%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
IMMED
POST OP
<2MONTHS >2M- 1Y >1Y-2Y >2 YEARS
CADAVER LIVE RELATED SPOUSAL
Bacterial pneumonia  peaks in the period of <2 months time since transplant whereas
tuberculosis and fungus pneumonia is commonly found in the period of >2 months to
2 years.
Figure 12
RISK FACTORS AND OCCURENCE OF INFECTION TIME SINCE
TRANSPLANT IN LOWER RESPIRATORY TRACT INFECTED PATIENTS:
Table 31
Time interval
of infection
Basilixi
mab
received
Atg
received
Pulse
steroids
Diabetic > 8
tacro
level
Hcv
Immediate
post op(7
days)
3 0 1 0 0 0
<2 months 3 1 0 0 3 0
>2 months -
2years
1 3 8 8 5 0
3 4 7 2
1
5
61
3
1
4 2
3
2
02
46
810
1214
1618
20
IMMEDIATE
POST OP(7
DAYS)
<2 MONTHS >2 MONTHS -
2YEARS
>2 YEARS
BACTERIAL TUBERCULOSIS
FUNGAL NO ORG ISOLATED
>2 years 0 0 0 3 0 3
Patients who received  basiliximab had infection in the period <2 months time since transplant
whereas patients who received ATG, who had diabetes, pulse steroids for rejection, >8ng/ml of
tacrolimus had infection more in the period of  >2 months to 2 years. Patients who had HCV
had pneumonia > 2 years of transplant.
Figure 13
DISCUSSION
Prevalence :
The prevalence of pneumonia in post renal transplant recipients in our study is
about 27.2% which correlates with the previous studies conducted by Gasink LB &
colleagues, Kutinova A et al & Tveit et al 7,8,9 which says was  about 2.9%- 30%.
The rate is on the higher side as India is a developing country and a number of factors
like unhygienic conditions, poor socio economic status and illiteracy play an
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important role in increasing the infection rate. The  patients have increased exposure
to environmental respiratory pathogens and poor socio economic status leading to
malnutrition thus increasing the net immunosuppression in addition to the
immunosuppressive drugs. (according to Rubin et al 33).
Gender difference:
Males constitute 85% (n=34)of the lower respiratory tract infection  compared
to females(n=6) which is about 15%. The difference is statistically significant
(p=<0.001).This correlates with the study conducted in Nizam institute of medical
science,  Hyderabad 13. 40.5% of the male transplant recipients had LRTI and 10% of
the female transplant recipients had LRTI .The increase in incidence in  males is due
to their frequent outdoor activities (increased environmental exposure)33 more than
females .Hence are exposed frequently to environmental pathogens.
Age distribution:
` In our study ,pneumonia is more prevalent in the age group of 21-40 years
(77.5%) which is similar to that in the study conducted in Nizam institute of medical
science,  Hyderabad 13 . The mean age is 32 in our study.
Lower respiratory tract infection rate based on donor type:
In our study, percentage of lower respiratory tract infection  is more in live
related transplant recipient patients (31.55%) compared to cadaver transplant
recipients (25.8%).Among the total 40 lower respiratory tract infected patients , most
of the infection occurred in live related transplant patients (57.5%) compared to
cadaveric transplant recipients (37.5%). But there is no statistical significance between
the two groups (P=0.33) for the occurrence of lower respiratory tract infection.
Risk factors such as  Basiliximab ,ATG , increased tacrolimus level are
associated more with cadaver transplants. Whereas  anti rejection therapies, diabetes
were more with live related transplant patients. Since there is a statistical  significance
between anti rejection therapy ( iv pulse steroids) and bacterial infection , the live
related transplant recipients are at more risk of bacterial infection.
Types of infection among the lower  respiratory tract infection patients:
Bacterial pneumonia:
In our study , bacterial infection is the most common infection (40%) than
other infection among the lower respiratory tract infected transplant recipients.. This
correlates with the  independent studies  conducted  by Alangaden GJ, Bonatti H,
Cervera C, Singh N et al 21,22,23,24.The bacterial pneumonia infection in our study in
renal transplants is about 10.88%(n=16) which is higher than in the study by Nina
Singh, M.D. and his colleagues which is about 4-5%. This is because of the  poor
hygiene, lower socio economic status of the people prevailing in developing countries
which adds to the increased percentage in Indian population.
The incidence of bacterial pneumonia peaked in the initial 4-8 weeks  which is
about 43.75% (n=7) which correlates with what is said by Nina Singh N and his
colleagues( 35-48%). This is because of the intense immunosuppression the patient
had received during this period that is the induction agents, increased dose  of the
maintenance triple drug regimen and anti rejection therapies if occurred.
In our study in the postoperative period Amp C producing Pseudomonas(n=1),
carbapenamase producing acinetobacter (n=1), Methicillin resistance Staph
aureus(n=1) are the  organisms causing the  infection. This clearly states these are
nosocomially acquired. Gram negative organisms are more than gram positive
organisms in the postoperative period. This correlates with the type of organism
isolated mentioned in these studies.25,10
In our study, after the initial post operative period organisms which caused
bacterial pneumonia were Haemophillus influenza , Klebsiella spp , Pseudomonas spp
, Staphylococcus aureus . This correlates with the study by Nina Singh 25.These may
me mostly community acquired. Resistance pattern is comparatively low when
compared to organism isolated in the initial post transplant period.
There is no incidence of nocardia pneumonia in our study. This may be  because
of the lifelong prophylaxis of cotrimoxazole given to the transplant recipients for
Pneumocystis carinii.
The risk factors associated with bacterial infection were basiliximab(n=3,
P=0.48), Anti thymocyte globulin (n=1, P=0.74), pulse steroids for rejection therapy
(n=6, P=0.03), diabetes (n=3, P=0.84), tacro level >8ng/ml (n=4, P=0.25). Induction
agents and increased tacrolimus level were associated in the earlier period whereas
pulse steroids and diabetes were associated in the later period. Intravenous pulse
methyl prednisolone administration for rejection given to the patients is statistically
associated with bacterial infection in our study(P=0.03). All these patients except
one (cadaver transplant- not received induction agent) are live related transplant
recipients who had not received any induction agents. Hence antirejection therapy has
statistical significance with bacterial infection since the immunosuppression is very
much intensified during the period.
Resistance pattern of the bacterial organisms isolated:
In the immediate postoperative period , multidrug resistant organisms were found
since the patient is exposed to hospital environment. Resistance is comparatively low
in the intermediate and later period. Most of the organisms isolated showed resistance
to cotrimoxazole since patient had been on lifelong prophylaxis for Pneumocystis
carinii pneumonia.
Pulmonary tuberculosis:
In our study, 8.1% (n=12)of the transplant patients are affected with
pulmonary tuberculosis. This is higher than the percentage in the study conducted in
Nizam institute of medical sciences (1.6%) 38 Pulmonary tuberculosis contributes
30% of the lower respiratory tract infection  in our study .The median age to develop
tuberculosis is 27 months. This nearly correlates with the study conducted by JIA Liu
et al  which is about 20 months.38 Majority of tuberculosis cases had occurred after
one year (n=8) in our study (66.66% ). This contradicts with these studies 42,43,44
which says the majority of tuberculosis cases had occurred within one year of
transplant. This may be because, the net state of immunosuppression is determined by
the sustained level of immunosuppression the patient had rather than the dosage of
the drug given during that period.33
Coming to the risk factors associated with the patients affected with pulmonary
tuberculosis, Anti thymocyte globulin was received by 2 patients, intravenous pulse
methyl prednisolone 3-5 doses for rejection were received by 4 patients, diabetes was
associated with 4 patients, >8 ng/ml of tacro level was seen in 1 patient and HCV was
seen in 1 patient. When Tuberculosis occurred within one years , the risk factors
associated are Anti thymocyte globulin (P=0.17), intravenous pulse methyl
prednisolone (P=0.40), diabetes (P=0.2),  >8 ng/ml of tacrolimus level (P=0.88).
Basiliximab received patients had no incidence of pulmonary Tb in our study. When
tuberculosis occurred after one year, diabetes and HCV (P=0.44) are the risk factors
associated in our study. Though these risk factors are said to be associated with the
development of Tuberculosis in various studies 26, 45,46,49,48 there is no  statistical
significance between these risk factors  and the development of pulmonary
tuberculosis in our study. There is no statistical significance for the occurrence of
pulmonary TB between diabetes under control and uncontrolled . Upper lobe of the
lung is the mostly affected in tuberculosis in our study 53.33%.
Fungal pneumonia:
The incidence of fungal pneumonia in our study is 3.4% (n=5) which correlates
with the study by Alangaden GJ, Sileri P et al which says is about 1-4%. 21,27. The
mortality rate is about 40% (n=2) in our study. Aspergillus is the common organism in
our study (60%) (n=3) followed by mucor species (40%) (n=2). The mortality rate is
66.66% (n=2). Most of the fungal infection has occurred after 3 months of
transplantation 80% (n=4). This is contradictory with the study by Gavalda et al 28
(majority of cases occurred within 90 days) but  correlates with the occurrence of
opportunistic infection in this period described by Rubin et .al33.
The risk factors associated with fungal pneumonia in our study were
basiliximab (n=2),  2-3 doses of intravenous pulse methyl prednisolone as
antirejection therapy (n=2) , uncontrolled diabetes (n=4), HCV (n=1), tacrolimus level
of 18.8 ng/ml (n=1). Basiliximab and high tacrolimus level are associated with fungal
infection within 2 months of transplant whereas diabetes and HCV are associated with
latter infection.
All the diabetic patients who had fungal infection had uncontrolled
hyperglycemia( 100%).Glycemic status of the diabetic patient had been an important
factor in our study. There is a statistical significance between diabetes and fungal
pneumonia in our study (P=0.002). Though intensified immunosuppression , anti
rejection therapies, chronic viral infection such as HCV were stated as risk factors for
fungal infection in transplant recipients  in these studies 28,31 there is no statistical
significance in our study. In our study  one patient had both tuberculosis and fungal
pneumonia and two patients had both bacterial and fungal pneumonia.
Most common lobe affected in fungal pneumonia patients is the upper lobe
80%. There is no incidence of Pneumocystis carinii reported in our patients. This is
due to the lifelong prophylaxis of Cotrimoxazole given for the patients.
Cytomegalovirus pneumonia:
In our study , one case of Cytomegalovirus pneumonia was reported (0.68%).
But the case was a late onset CMV (4.5 years since transplant). The viral load was
about 1,23,254copies/ml in the plasma. Owl's eye intra nuclear  inclusion bodies were
positive from the lung biopsy sample. The risk factor associated were diabetes  and
Azathioprine based regimen for the patient. pp65 antigenemia for other patients
suspected to have CMV were negative.
Other viral  and atypical pneumonia:
Though a number of viruses  other than CMV and atypical organisms cause
pneumonia  in transplant recipients, due to limitations in availability of
investigations,  it is not done in our study and hence comment about viral and atypical
pneumonias could not be made out. In our study, in 11 patients, organisms could not
be obtained though the patients had signs and symptoms suggestive of pneumonia.
These could be due to these organisms.
Basiliximab:
A total of 20 patients had received Basiliximab among the total 147 patients.
The rate of lower respiratory tract infection among Basiliximab received patients in
our study is about 35%(n=7). In our study 85.7%(n=6) of the Basiliximab received
patients had lower respiratory tract infection within 2 months. Basiliximab saturates
IL- 2 receptors for 4-6 weeks14. No incidence of TB is reported in Basiliximab
received patients.
According to the various studies conducted, there is no increase noted in the
incidence of CMV, fungal and bacterial infections for Basiliximab when compared to
placebo or other therapies for induction 18,19,20. Our study also correlates with these
studies since there is no statistical significance in the occurrence of lower respiratory
tract infection (P=0.8) with the administration of Basiliximab. There is no statistical
significance in the incidence of  bacterial (P=0.48) and fungal infection(P=0.07) in
Basiliximab received patients in our study.
Anti Thymocyte Globulin:
A total of 9 patients had received  ATG as induction agent. The rate of lower
respiratory tract infection is 44.44% (n=4) in these patients. 2 patients had pulmonary
tuberculosis. Though  lymphocyte depleting agents are  considered as risk factors
associated with tuberculosis in renal transplant recipients in these studies 45,46,49 there
is no statistical significance in the occurrence of tuberculosis in ATG received patients
in our study (P=0.17). In the  study conducted by Midtvedt K et al ,ATG has been
associated with increased incidence  of pneumonia, bacteremia or sepsis . 56 But there
is no statistical significance between ATG induction and bacterial  infection in our
study (P=0.74). Our study correlates with the study conducted by Chinese from Feb.
2007 to Jul. 2012  which says there is no  increase in incidence of infection in patients
received ATG since there is no statistical significance between ATG and lower
respiratory tract infection in our study (P=0.88%). According to the study by Steven
D. Burdette et al ,ATG induction in renal transplants  does not lead to any  increase in
incidence of fungal infection.14 This correlates with our study as there is no incidence
of fungal pneumonia in our study.
Comparison between Basiliximab and ATG:
The rate of lower respiratory tract infection occurred is more in ATG (44.44%)
than Basiliximab (35%) in our study. But there is no statistical significance between
the two (P=0.68) in causing lower respiratory tract infection. This correlates with the
study conducted by Chinese 16 from Feb 2007- 2012 (P>0.05) . But contradicts with
the study conducted by Brennan DC et al 18.
Intravenous pulse methyl prednisolone for anti rejection:
In our study , 22.5% of the lower respiratory tract infection patients had received
pulse steroids as anti rejection therapy. In our study, it was associated with highest
bacterial  infection rate (66.66%). There is a statistical significance between anti
rejection therapy pulse steroids and bacterial pneumonia in our study (P=0.002).
The mean duration between administration and pneumonia is about 18 months in our
study. In our study,  the patients  who received anti rejection therapy were live related
transplants and did not receive any induction agents . There is an indirect association
between rejection and bacterial pneumonia . There is no statistical significance
between fungal and tuberculosis infection (P=0.4) related to pulse steroids (P=0.5%)
in our study though it is considered as risk factor in these studies 45,46,47, 28. In our
study, 88.88% of the patients  who received anti rejection therapy had pneumonia
within 2 years of transplant .
Diabetes (including NODAT):
In our study, 11 patients with respiratory tract infection had diabetes (including
10 NODAT + 1 pre transplant DM). In our study, the lower respiratory tract infection
rate among diabetes patients is  27.5%. But there is no statistical significance
between pneumonia and diabetes in our study (P=0.73). The percentage of
tuberculosis (36.36%) and fungal pneumonia (36.36%) is more than bacterial
pneumonia (27.27%) in our study. Diabetes had statistical significance with fungal
pneumonia in our study (P=0.001). This correlates with the study by 31,32.  All the
patients with fungal pneumonia who are diabetic  had poorly controlled diabetes and
patients who have diabetes under control had no incidence of fungal infection .This
correlates with the study by Bhansali et al 62 . Though diabetes is considered a risk
factor for tuberculosis(P=0.2) and bacterial infection (P=0.84) in various studies by
John GT et al in transplant recipients 48, there is no statistical difference in our study.
In our study 72.72% (n=8) of the patients who had diabetes , the infection
occurred after 1 year of transplant. In our study 4 patients with diabetes had received
pulse steroids for rejection , 2 had ATG, 1 had Basiliximab. In patients who received
ATG and had NODAT, the infection occurred within 1 year of transplant. One patient
with diabetes had CMV infection.
HCV infection:
In our study, 7.5% of the lower respiratory tract infection patients  had HCV
infection(n=3) .All had pneumonia after 5 years of transplant. This correlates with
Rubin et all 33 study which says patients with chronic infection with
immunomodulating virus such as HBV, HCV etc  present with secondary infection in
the later period. There is no statistical significance between HCV and bacterial (n=0)
, fungal (P=0.12) and tuberculosis (P=0.44) infection in our study though it is
considered as risk factors in various studies 45,46,49,31.
Increased Tacrolimus level:
In our study 20% of the patients with lower respiratory tract infection had
Tacrolimus level >8ng/ml at the time of infection. There is no statistical difference
between increased trough level of Tacrolimus and bacterial (P=0.25), fungal (P=0.5),
tuberculosis (P=0.88) infection at the time of infection. This is because the infection is
directly related to duration of  sustained immunosuppression rather than the duration
of the dose at a particular time by Rubin et al 33. We rather need to study about the
duration the patient had exposed to higher Tacrolimus level  which will give a better
idea if the Tacrolimus level is influencing the occurrence of pneumonia. Since all the
patients are receiving Tacrolimus in the triple drug maintenance regimen, individual
attribute of the drug to a particular infection cannot be made out . Only the trough
level of the drug can be correlated  to infection.
MMF and oral prednisolone:
Since all renal transplant recipients received MMF and oral prednisolone as a
part of triple drug maintenance therapy lifelong and their serum levels are not
monitored, risk of infection associated independently with these drugs could not be
made out in our study.
TIME SINCE TRANSPLANT:
Early post transplantation period: <2 months/period of intense immune
suppression:
Bacterial pneumonia  is the most common infection during this period in our
study. And the bacterial organisms isolated in the immediate post operative period are
nosocomial acquired and are multidrug resistant. Only one case of opportunistic
fungal infection was seen in our study within 2 months. The patient must  had intense
immunosuppression since the tacrolimus level was 18.8ng/ml and had basiliximab for
induction. Basiliximab is the risk factor most commonly associated within this period.
Here the patient's pretransplant status and the duration of surgery, surgical skills,
nosocomial exposure to pathogens play a role in addition to the immunosuppression
given by the drugs.
Intermediate period :>2months - 2year period:
Most of the lower respiratory tract infection had occurred during this
period(40%). This is because of the sustained immunosuppression the patient had
exposed to. During this period, community acquired pathogens such as tuberculosis,
Haemophillus and opportunistic fungal  infection has caused increased incidence of
pneumonia in our study. Diabetes and pulse steroids for rejection the patient had
received were the major risk factors  found in patients who had pneumonia during this
period.
Late post transplant period (>2 years):
During this period tuberculosis, opportunistic fungal infection causing pneumonia
is mostly found. The risk factors found are immunomodulating virus HCV and
diabetes.
Limitations of Rubin's table for present application:
The study was conducted in the year 1998. The study was based mostly on the
tacrolimus or cyclosporine based regimen. The table concludes a risk of infection
more in the period of 1-6 months. But in our study it was more in the period of 1 to 2
years.  Since no induction therapies were used during this period , the table cannot be
applied as such and slighter modifications were needed for the time interval. This is
also concurred by the study conducted in Nizam Institute of Medical Sciences of
Hyderabad which showed increased risk of infection from 1 to 3 years. 13
SUMMARY
This  study was conducted to find the prevalence of lower respiratory tract
infections  in post renal transplants in a tertiary care hospital between September 2014
to August 2015.  From a total of 147 patients, 40 patients had lower respiratory tract
infections . The details of some patients were collected retrospectively and for the
other patients processing is done to find out the type of organism.
The prevalence of lower respiratory tract infection in renal transplant
recipients in our study is about 27.2%. It is more common in males (39.08%)
compared to females (10%) due to increased environmental exposure (P=<0.001). It is
more common in 20-40 yrs of age group (77.5%).Though the percentage of
pneumonia  is more common in live related transplant recipient patients compared to
cadaveric transplant recipients , there is no statistical significance between the two
(P=0.33).
Bacteria (40%) is the most common cause of pneumonia in our study
followed by tuberculosis (30%) , fungal pneumonia (12.5%) and CMV (2.5%).
The rate of bacterial pneumonia is 10.8%, the rate of  pulmonary
tuberculosis  is 8.16%, the rate of fungal pneumonia is 3.4% and CMV is 0.68%
among the total renal  transplant recipients
Cadaveric transplant recipients are associated with more risk factors
than live related transplants. But pulse steroids are more in live related transplants.
Diabetes (27.5%) is the leading risk factor associated with  lower respiratory tract
infection patients (27.5%) , followed by pulse steroids (22.5%)  which is given for
rejection.
In the association of specific risk factors with specific infection by
proportion test, only pulse steroids given for rejection  had statistical significance with
bacterial pneumonia (P=0.03) and diabetes had statistical significance with fungal
pneumonia (P=0.002). The rate of lower respiratory tract infection occurred is more in
ATG (44.44%) than Basiliximab (35%) but there is no statistical significance between
the two (P=0.68)
Basiliximab (P=0.8) , ATG (P=0.88), Diabetes (P=0.73) had no
statistical significance with lower respiratory tract infection in renal transplant
recipient patients.
Aspergillus and Mucor were the fungal species causing pneumonia in our
study. Fungal pneumonia had a mortality rate of 66.66% in our study. All the diabetes
patients with fungal pneumonia (n=4) had poorly controlled glycemic status.
Most of the lower  respiratory tract infection had occurred  in the duration
of >2 months to 2 years (40%) after transplantation. Up to 1 year time since
transplant, lower respiratory infection was more common in cadaveric transplant
recipients (60%). After 1 year , it was common in live related transplant recipients
(80%).
In our study, bacterial pneumonia  peaked  in the period of <2 months time
since transplant whereas tuberculosis and fungus pneumonia were commonly found in
the period of >2 months to 2 years.
Patients who received  Basiliximab had infection in the period <2 months
time since transplant whereas patients who received ATG, who had diabetes, pulse
steroids for rejection, >8ng/ml of Tacrolimus had infection more in the period of  >2
months to 2 years. Patients who had HCV had pneumonia > 2 years of transplant.
Nosocomially acquired multidrug resistant bacterial organisms  dominated
during the earlier post transplant period followed by community acquired tuberculosis,
other bacterial organisms and opportunistic fungal organisms in the intermediate and
later period.
CONCLUSION
The prevalence of lower respiratory tract infection in renal transplant recipients
in  our hospital is about 27.2%.
There was a higher incidence of fungal pneumonia in poorly controlled
diabetes patients.
Patients who received intravenous pulse methyl prednisolone for rejection had
higher incidence of bacterial infection.
Induction therapy was not associated with increase in incidence of infection.
Since patient is on lifelong prophylaxis of cotrimoxazole, there is a higher
increase of resistance to it.
FUTURE PROSPECTIVE:
Since anti rejection therapy in renal transplant recipients had statistical
significance with the association of bacterial infection and those patients had not
received induction agents, a comparative study for the occurrence of infection
between patients who received induction agents and not received need be done.
Since the median time to develop pneumonia is 18 months from the
administration of intravenous pulse steroids for rejection, other infections associated
with their administration have to be studied in detail.
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